On March 8, 2022 Australian clinical-stage drug development company Noxopharm (ASX:NOX) reported its Phase 1 CEP-2 sarcoma trial is underway with a first patient enrolled and dosed at City of Hope in Los Angeles, California (Press release, Noxopharm, MAR 8, 2022, View Source [SID1234609691]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted to have dosed the first patient in the CEP-2 trial," said City of Hope CEP-2 Principal Investigator Mark Agulnik, M.D. "The study investigates the use of Veyonda in combination with the chemotherapy drug doxorubicin for first-line treatment of approximately 30 patients with soft tissue sarcoma, which is an aggressive cancer in urgent need of new treatment options."
City of Hope, a world-renowned cancer center in the U.S., is the first site to commence treatment, but recruitment is ongoing and Noxopharm plans to open future major U.S. trial sites.
"Partnering with the prestigious City of Hope for this CEP-2 study, along with the MD Anderson Cancer Center and Beverly Hills Cancer Center for our radiation therapy trial [DARRT] program, represents the strength of our programs and the talent and experience of our team at Noxopharm," said Noxopharm CEO and Managing Director Gisela Mautner, M.D.-Ph.D., MPH. "We look forward to adding additional prestigious study sites in the near future as we all work toward new treatment options."
The first safety results for the CEP-2 study will be available after patient cohort 1 has completed the first cycle of combination therapy. The CEP-2 study is building on the CEP-1 study, which was a Phase 1a/1b trial that was published in April 2021 in the peer-reviewed journal Current Therapeutic Research, and showed the success of Veyonda in boosting the efficacy and safety of chemotherapy in late-stage cancer patients.